Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
about
An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesCytogenetic and molecular abnormalities in chronic myelomonocytic leukemiaNew ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromeRecent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemiaDecitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience.A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.The search for better prognostic models in myelodysplastic syndromesCriteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia.5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature.Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and MarrowChronic myelomonocytic leukemia: Forefront of the field in 2015.The use of hypomethylating agents in the treatment of hematologic malignancies.Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trialTreatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia.Chromatin, cancer and drug therapies.Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias.A forgotten cause of kidney injury in chronic myelomonocytic leukemia.Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.Is acute myeloid leukemia a liquid tumor?Current status of allogeneic HST for chronic myelomonocytic leukemia.Promises and challenges of anticancer drugs that target the epigenome.Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.Emerging targeted therapies in myelofibrosis.Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groupsI walk the other line: myelodysplastic/myeloproliferative neoplasm overlap syndromes.A case of sudden hearing loss during treatment with decitabine for chronic myelomonocytic leukemia.Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.Clinical analysis of NSCLC patients reveals lack of association between EGFR mutation and TET1 downregulation.Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States.Treatment of chronic myelomonocytic leukemia with 5-azacytidine: case reports.Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.p53 and DNA methylation suppress the TRAIN to cell death.High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study.Lysozyme-Induced Nephropathy.
P2860
Q24622700-773127FB-AE75-4F69-BB4C-664F907A020EQ26768600-0887F38B-87B2-443D-B0C5-4FCEAE3987A3Q26829132-97D5DCE2-9132-4A1A-8665-0371CEF26171Q28307278-6628E4BF-BEEA-4DAC-B58C-5233D2039CF1Q33392205-5D98CCB3-84F4-4357-8F84-FF906A7EE571Q33442672-CA46D7CF-9516-4916-9DF9-6588773D081FQ33600822-0FCF192F-3D34-4B8A-AF1E-83F602C71C02Q34386812-0B49C4BE-ED3D-469E-9917-6E8F8238E47BQ34797988-73D2E4CC-E50B-472A-949D-37CB3B92F3E0Q35010676-F26443B3-4F4B-434F-9741-C23A68E396DCQ35556061-251ADA6F-214C-4AC9-8480-0AFCE433823FQ35714782-998D8C97-6E39-40E3-A079-EC6481F7D0B1Q36876853-2D4959CC-CE3A-4228-89B8-F5E860C3260CQ36929658-5A5D339B-85E9-412B-8451-C709320E1F31Q36934269-E1AFAEEA-F809-482B-BC5D-2ED0F144C694Q36967029-91ED9036-06DC-41A1-90B0-3966209EF5F5Q37073231-75B9E849-7EBB-44EC-9DB1-C2B6C0689739Q37184917-22A769E8-7CD1-4BF6-B9ED-BED20C5B6912Q37299461-B1DA59FC-E5F8-42D8-AE4D-130DD0C6C1F3Q37349392-A21F00C3-1F38-46F9-9B06-5CCC9C450572Q37522963-BEBA61F8-F488-40D9-918F-5AB2E9DA38ACQ37899751-EEFC8D1A-7589-43D2-8ADF-FDB0220A63C5Q37962596-C2D145C6-ABCB-4209-A14A-3A780DF92EC5Q38012085-FA15D1FA-A75E-4E84-AD5A-175E9351BECAQ38025160-25D03C6C-DC02-46A7-A2BD-1A17614AC65FQ38130476-B81EA68B-6724-45CA-A62C-366F624E3D06Q38134374-2ABAEB28-409D-4B5D-B1E5-A2ED31510CADQ38246598-EFF82F40-697F-4686-97F7-E52A1FEB9473Q38440190-BAF0E38A-14AE-4E52-A802-EF0F9E4C885EQ38540013-8D82B038-6754-4810-8BC9-E52F28DB8318Q38641499-CE4637A2-E66E-46F1-9E7F-C1C8B9B10DA0Q38835771-ACE542A8-5C46-4292-A96C-B436FF675485Q38859646-DDC430AA-4570-409F-BC73-517B736D2B73Q39158385-8C84D872-4AD1-48C7-86C3-76EBB18FA7BFQ39560322-FEE5A600-FF9D-40B4-926E-0C518AEA0CE8Q40157327-FB4845CC-CBA9-45CD-9275-9BFE0AD3BD7EQ40421122-A575CE72-C756-4A0F-ACCF-0CA78FF55F49Q43249171-30A4B927-328F-4BDA-9861-E1E7A81DFBD2Q45358400-559035EE-047F-4CA4-A2F5-E82461BEA990Q45796936-E90DD8F6-4F37-40A1-A40B-E2F93DA8A48D
P2860
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
@ast
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
@en
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
@nl
type
label
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
@ast
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
@en
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
@nl
prefLabel
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
@ast
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
@en
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
@nl
P2093
P50
P356
P1433
P1476
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
@en
P2093
Ahmed Aribi
Jan Davisson
Jianqin Shan
P304
P356
10.1002/CNCR.22457
P407
P577
2007-02-01T00:00:00Z